Combination treatment shows early promise for metastatic pancreatic ductal cancer

A combination of several small doses of an investigational radioimmunotherapy and the chemotherapy gemcitabine had superior outcomes compared with radioimmunotherapy alone in patients with metastatic pancreatic ductal cancer, according to phase Ib clinical trial data presented at the AACR special conference, Pancreatic Cancer: Innovations in Research and Treatment, in New Orleans, Louisiana.

Oncology Nurse Advisor